Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Bowden

Showing results (271-280 of 281) with videos related to

Pageof 29
Sort By:
The Journal of Allergy and Clinical Immunology. in Practice|June 17, 2023
Impact of Landscape Fire Smoke Exposure on Patients With Asthma With or Without Laryngeal HypersensitivityAnne E Vertigan, Erin S Harvey, Tesfalidet Beyene, et al.
Internal Medicine Journal|June 29, 2016
Effectiveness and response predictors of omalizumab in a severe allergic asthma population with a high prevalence of comorbidities: the Australian Xolair RegistryP G Gibson, H Reddel, V M McDonald, et al.
Allergy|August 26, 2023
Biologics (mepolizumab and omalizumab) induced remission in severe asthma patientsDennis Thomas, Vanessa M McDonald, Sean Stevens, et al.
The Lancet. Oncology|May 9, 2017
Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised, phase 3 trialHelena M Earl, Louise Hiller, Helen C Howard, et al.
The Journal of Allergy and Clinical Immunology. in Practice|February 5, 2021
Mepolizumab and Oral Corticosteroid Stewardship: Data from the Australian Mepolizumab RegistryDennis Thomas, Erin S Harvey, Vanessa M McDonald, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|July 6, 2016
Real-life effectiveness of omalizumab in severe allergic asthma above the recommended dosing range criteriaM Hew, A Gillman, M Sutherland, et al.
British Journal of Cancer|October 11, 2012
Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer: results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trialsH M Earl, L Hiller, J A Dunn, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|April 21, 2018
Working while unwell: Workplace impairment in people with severe asthmaS A Hiles, E S Harvey, V M McDonald, et al.
Nature Medicine|July 6, 2023
SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive diseaseEleanor Barnes, Carl S Goodyear, Michelle Willicombe, et al.
The Lancet. Rheumatology|May 11, 2024
Immunogenicity of third dose COVID-19 vaccine strategies in patients who are immunocompromised with suboptimal immunity following two doses (OCTAVE-DUO): an open-label, multicentre, randomised, controlled, phase 3 trialCarl S Goodyear, Amit Patel, Eleanor Barnes, et al.
Pageof 29

Showing results (271-280 of 281) with videos related to

Sort By:
Pageof 29
The Journal of Allergy and Clinical Immunology. in Practice|June 17, 2023
Impact of Landscape Fire Smoke Exposure on Patients With Asthma With or Without Laryngeal HypersensitivityAnne E Vertigan, Erin S Harvey, Tesfalidet Beyene, et al.
Internal Medicine Journal|June 29, 2016
Effectiveness and response predictors of omalizumab in a severe allergic asthma population with a high prevalence of comorbidities: the Australian Xolair RegistryP G Gibson, H Reddel, V M McDonald, et al.
Allergy|August 26, 2023
Biologics (mepolizumab and omalizumab) induced remission in severe asthma patientsDennis Thomas, Vanessa M McDonald, Sean Stevens, et al.
The Lancet. Oncology|May 9, 2017
Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised, phase 3 trialHelena M Earl, Louise Hiller, Helen C Howard, et al.
The Journal of Allergy and Clinical Immunology. in Practice|February 5, 2021
Mepolizumab and Oral Corticosteroid Stewardship: Data from the Australian Mepolizumab RegistryDennis Thomas, Erin S Harvey, Vanessa M McDonald, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|July 6, 2016
Real-life effectiveness of omalizumab in severe allergic asthma above the recommended dosing range criteriaM Hew, A Gillman, M Sutherland, et al.
British Journal of Cancer|October 11, 2012
Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer: results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trialsH M Earl, L Hiller, J A Dunn, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|April 21, 2018
Working while unwell: Workplace impairment in people with severe asthmaS A Hiles, E S Harvey, V M McDonald, et al.
Nature Medicine|July 6, 2023
SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive diseaseEleanor Barnes, Carl S Goodyear, Michelle Willicombe, et al.
The Lancet. Rheumatology|May 11, 2024
Immunogenicity of third dose COVID-19 vaccine strategies in patients who are immunocompromised with suboptimal immunity following two doses (OCTAVE-DUO): an open-label, multicentre, randomised, controlled, phase 3 trialCarl S Goodyear, Amit Patel, Eleanor Barnes, et al.
Pageof 29